Prediction: Synopsys Could Hit $600+ in 12 Months and Here’s Why

Photo of Vandita Jadeja
By Vandita Jadeja Published

Quick Read

  • Synopsys (SNPS) reported Q1 FY2026 revenue of $2.41B, up 65.4% YoY with non-GAAP EPS of $3.77 beating consensus, while the company carries a $11.4B backlog and generated $856.8M in operating cash flow in the quarter, funding $3.45B in debt paydown and a $2B buyback.

  • AI-driven chip design demand is accelerating customer R&D spending and lifting Synopsys’ revenue guidance, though China export restrictions affecting roughly 10% of revenue and heavy debt of $10B remain key risks to monitor.

  • The analyst who called NVIDIA in 2010 just named his top 10 stocks and Synopsys wasn't one of them. Get them here FREE.

Prediction: Synopsys Could Hit $600+ in 12 Months and Here’s Why

© 24/7 Wall St.

Synopsys (NASDAQ:SNPS | SNPS Price Prediction) has whipsawed investors over the past year, from an August 2025 peak near $617.91 to a November low of $389.83, before settling at $498.43. With the Ansys integration now fully reflected in results and AI-driven chip design demand intact, our model sees room to run.

Our 24/7 Wall St. price target for Synopsys is $607.31, implying 21.84% upside over the next 12 months. The recommendation is buy, with a confidence score of 90%, which we consider high.

An infographic titled 'Synopsys (SNPS) NASDAQ 12-Month Price Prediction' from 24/7 Wall St. The design uses a green and white color scheme on a dark background. The 'THE CALL' section shows a current price of $498.43 and a price target of $607.31, indicating '+21.84% UPSIDE' and a 'BUY' recommendation with 'High Confidence (90%)'. The 'HOW WE GOT THERE' section lists Trailing P/E Based Price as $498.43, Forward P/E Based Price as $541.70, Analyst Avg Target as $537.53, and Weighted Base Price as $531.80. 'OUR ADJUSTMENTS' detail Tech Sector Momentum at +15% (Multiplier), Analyst Consensus at +3.8%, and Earnings Growth/Volatility at -3.5%, leading to a 'FINAL TARGET' of $607.31. The 'BULL CASE: WHAT COULD GO RIGHT' section outlines factors like AI-Fueled Chip Design Demand, $11.4B Backlog & Strong Cash Flow, and $2B Buyback Program Replenished, with a target of $681.83. The 'BEAR CASE: WHAT COULD GO WRONG' section lists potential risks such as China Export Restrictions (~10% Revenue Risk), Heavy Debt Load Post-Ansys (~$10B), and Design IP Segment Margin Collapse (to 20.1%), with a target of $526.69. The 'THE BOTTOM LINE' section reiterates a 'BUY' rating and Price Target of $607.31 (+21.84%), followed by a summary of driving factors and risks.
24/7 Wall St.

24/7 Wall St. Price Target Summary

Metric Value
Current Price $498.43
24/7 Wall St. Price Target $607.31
Upside 21.84%
Recommendation BUY
Confidence Level 90%

A Volatile Path Back to $500

Synopsys is up 10.87% over the past month and 6.11% year to date, though shares slipped 3.44% in the last week. The stock trades 18% below its 52-week high of $651.73 and well above the $376.18 low.

Q1 FY2026, reported February 25, delivered revenue of $2.41 billion, up 65.4% YoY, and non-GAAP EPS of $3.77, beating consensus by 5.98%. Management reiterated FY2026 guidance of $9.56B to $9.66B in revenue and non-GAAP EPS of $14.38 to $14.46. Memorable for shareholders: the Q3 FY2025 miss triggered a 35.84% single-day drop before a recovery began.

The Case for $680+

Bulls have plenty to point to. CEO Sassine Ghazi said “Synopsys enters 2026 with an expanded portfolio, leadership positions across the business, and the most compelling roadmap in our history.” AI-fueled chip design demand is accelerating R&D spend at customers, and Synopsys carries a $11.4B backlog.

Operating cash flow swung to $856.8M in Q1 FY2026 from negative $67M, funding aggressive debt paydown of $3.45B in a single quarter and a replenished $2B buyback.

Wall Street is constructive: 15 Buy and 2 Strong Buy ratings versus 1 Strong Sell, with an average target of $537.53. Our bull case scenario sees Synopsys reaching $681.83 by May 2027, a 36.8% return, if Ansys synergies and AI tailwinds compound.

The Risks Worth Watching

The bear case starts with China. U.S. export restrictions touched roughly 10% of revenue and forced a guidance withdrawal in mid-2025. Debt remains heavy at $10B long-term, GAAP profitability is depressed by $404M in acquired intangible amortization, and the Design IP segment showed margin collapse from 36.7% to 20.1% in Q3 FY2025. Trailing P/E sits at 77, which leaves little room for error.

GAAP weakness stems from acquisition accounting and intangible amortization rather than core operating performance. Non-GAAP EPS guidance of $14.42 at the midpoint implies a forward P/E near 36, far more reasonable. The bear scenario takes SNPS to $526.69, still slightly positive.

Our Take: BUY Rated With High Confidence

The 24/7 Wall St. price target of $607.31 with 90% confidence earns a buy. The tipping factor is cash generation: $2.2B in operating cash flow funds buybacks and debt paydown while AI demand carries the topline. The bull thesis strengthens if Design IP stabilizes and China headwinds don’t worsen. It weakens if export restrictions broaden or Ansys synergies slip past 2027.

Year 24/7 Wall St. Price Target
2026 $607
2027 $682
2028 $770
2029 $845
2030 $904

These projections assume Synopsys executes on Ansys synergies and AI-fueled design demand persists. Significant upside or downside could result from China export policy shifts or material changes to the EDA competitive landscape.

Photo of Vandita Jadeja
About the Author Vandita Jadeja →

Vandita Jadeja is a financial copywriter who loves to read and write about stocks. She believes in buying and holding for long term gains. Her knowledge of words and numbers helps her write clear stock analysis. She has contributed to several publications, including the Joy Wallet, Benzinga, The Motley Fool and InvestorPlace.

Continue Reading

Top Gaining Stocks

MU Vol: 48,400,556
KR Vol: 4,357,845
INTC Vol: 108,478,374
AMT Vol: 2,362,226
DXCM Vol: 6,175,183

Top Losing Stocks

CTRA Vol: 73,319,495
BLDR Vol: 1,311,947
EL Vol: 2,295,172
ZBRA Vol: 602,361
MRNA Vol: 3,200,094